VitaSpring Biomedical Co. Ltd.
VSBC · OTC
1/31/2023 | 1/31/2022 | 1/31/2021 | 1/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $6 | $0 | $0 |
| % Growth | -100% | 2,161.6% | 1,539.4% | – |
| Cost of Goods Sold | $0 | $4 | $0 | $0 |
| Gross Profit | -$0 | $2 | $0 | $0 |
| % Margin | – | 36.8% | 45.2% | 11.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $1 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $0 | $0 |
| Operating Expenses | $4 | $1 | $1 | $0 |
| Operating Income | -$4 | $1 | -$0 | -$0 |
| % Margin | – | 26.4% | -171.4% | -128.7% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$4 | $1 | -$0 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$4 | $1 | -$0 | $0 |
| % Margin | – | 22.5% | -171.4% | 45.7% |
| EPS | -0.02 | 0.006 | -0.005 | 0 |
| % Growth | -431.1% | 229.8% | -1,275% | – |
| EPS Diluted | -0.02 | 0.006 | -0.005 | 0 |
| Weighted Avg Shares Out | 207 | 206 | 91 | 55 |
| Weighted Avg Shares Out Dil | 207 | 206 | 91 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | $1 | -$0 | -$0 |
| % Margin | – | 26.6% | -170.9% | -125.7% |